These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 1709294

  • 1. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C, Coleman DL.
    Schweiz Med Wochenschr; 1991 Mar 23; 121(12):397-412. PubMed ID: 1709294
    [Abstract] [Full Text] [Related]

  • 2. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
    Lehrnbecher T.
    Klin Padiatr; 2001 Mar 23; 213(4):212-38. PubMed ID: 11528556
    [Abstract] [Full Text] [Related]

  • 3. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF, Chan HO.
    Pharmacotherapy; 2005 Mar 23; 25(3):372-8. PubMed ID: 15843284
    [Abstract] [Full Text] [Related]

  • 4. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
    Borota R, Borota J, Belić A, Gebauer E, Stefanović N.
    Med Pregl; 1997 Mar 23; 50(3-4):87-93. PubMed ID: 9229690
    [Abstract] [Full Text] [Related]

  • 5. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R.
    Cancer; 2003 Dec 01; 98(11):2410-9. PubMed ID: 14635076
    [Abstract] [Full Text] [Related]

  • 6. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W, Wörmann B, Reuter C, Schleyer E, Zühlsdorf M, Böckmann A, Büchner T.
    Semin Oncol; 1994 Dec 01; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [Abstract] [Full Text] [Related]

  • 7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec 01; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 8. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O, Foss B, Petersen H.
    Eur Cytokine Netw; 2001 Dec 01; 12(2):231-8. PubMed ID: 11399510
    [Abstract] [Full Text] [Related]

  • 9. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
    Greenberg PL, Negrin R, Nagler A.
    Cancer Surv; 1990 Dec 01; 9(1):199-212. PubMed ID: 2276114
    [Abstract] [Full Text] [Related]

  • 10. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR.
    J Natl Cancer Inst; 2007 Feb 07; 99(3):196-205. PubMed ID: 17284714
    [Abstract] [Full Text] [Related]

  • 11. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
    Neidhart JA.
    Cancer; 1992 Aug 15; 70(4 Suppl):913-20. PubMed ID: 1379115
    [Abstract] [Full Text] [Related]

  • 12. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO.
    Bone Marrow Transplant; 1996 Jun 15; 17(6):951-6. PubMed ID: 8807099
    [Abstract] [Full Text] [Related]

  • 13. Colony stimulating factors.
    Klingemann HG, Eaves CJ.
    Bone Marrow Transplant; 1988 May 15; 3(3):177-84. PubMed ID: 2458788
    [Abstract] [Full Text] [Related]

  • 14. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
    Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ, Bowers CE, Niemeyer R, McIntyre W, Vrahnos D, Auberry SE, Spitzer G.
    Bone Marrow Transplant; 1996 Jul 15; 18(1):93-102. PubMed ID: 8832001
    [Abstract] [Full Text] [Related]

  • 15. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
    Sakamoto KM, Gasson JC.
    Int J Cell Cloning; 1991 Nov 15; 9(6):531-41. PubMed ID: 1770227
    [Abstract] [Full Text] [Related]

  • 16. [Hematopoietic growth factors in prevention and therapy of infectious complications in premature and newborn infants].
    Lehrnbecher T.
    Z Geburtshilfe Neonatol; 2001 Nov 15; 205(5):167-73. PubMed ID: 11727663
    [Abstract] [Full Text] [Related]

  • 17. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 15; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 18. Clinical applications of recombinant human colony-stimulating factors.
    Klingemann HG.
    CMAJ; 1989 Jan 15; 140(2):137-42. PubMed ID: 2642725
    [Abstract] [Full Text] [Related]

  • 19. [Myeloid hemopoietic growth factors. Therapeutic possibilities and clinical experiences].
    Hansen B, Johnsen HE.
    Ugeskr Laeger; 1990 Oct 29; 152(44):3232-7. PubMed ID: 1700524
    [Abstract] [Full Text] [Related]

  • 20. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan 29; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.